In human prostate cancer LNCaP and PC-3 cells, Shukla et al. demonstrated that apigenin treatment increased phosphorylation of ERK1/2 and JNK1/2 and decreased phosphorylation of p38. Here, MAPK3 is linked to prostate carcinoma.